Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...

Pharma stocks draw interest as pipelines, clinical trials and acquisitions support growth outlook despite patent expiry ...